Nektar Therapeutics (NKTR) and TrialNet said Monday that they agreed to collaborate to evaluate Nektar's drug, rezpegaldesleukin, in patients with new onset stage 3 type 1 diabetes mellitus.
Under the agreement, the companies said TrialNet will conduct a phase 2 trial involving about 70 adults and children to assess the safety and potential efficacy of the treatment, while Nektar will provide rezpegaldesleukin and support the study with pharmacokinetic analyses and other evaluations.
The companies said Nektar will retain all rights to the drug under the agreement.
The study will measure the drug's efficacy using a mixed meal tolerance test to assess C-peptide levels over a 12-month period, which includes a 6-month treatment phase and a 6-month follow-up, the companies said, adding secondary objectives include evaluating pharmacokinetics, pharmacodynamics, HbA1c levels, and insulin requirements.
Financial details of the partnership were not disclosed.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。